Terumo
4543.TPrecision Instruments
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥1.13T | ¥1.04T | ¥921.9bn | ¥820.2bn | ¥703.3bn | ¥613.8bn |
| Operating income | ¥176.3bn | ¥157.7bn | ¥140.1bn | ¥117.3bn | ¥116.0bn | ¥98.4bn |
| Net income (owners) | ¥135.9bn | ¥117.0bn | ¥106.4bn | ¥89.3bn | ¥88.8bn | ¥77.3bn |
| Total assets | ¥2.31T | ¥1.83T | ¥1.83T | ¥1.60T | ¥1.47T | ¥1.35T |
| Net assets / equity | ¥1.58T | ¥1.37T | ¥1.33T | ¥1.11T | ¥1.01T | ¥856.7bn |
| Operating cash flow | ¥230.9bn | ¥210.8bn | ¥146.3bn | ¥117.5bn | ¥141.5bn | ¥121.5bn |
| EPS (basic) | ¥92.14 | ¥79.01 | ¥71.5 | ¥59.5r | ¥58.72r | ¥51.16r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 86 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 86 figures · EDINET |
25 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Blood And Cell Technologies Company | ¥231.0bn | ¥33.6bn |
| Cardiac And Vascular Company | ¥676.4bn | ¥164.0bn |
| Medical Care Solutions Company | ¥216.1bn | ¥21.6bn |
| Terumo Organ Technologies | ¥8.0bn | ¥1.7bn |
| Adjustments & eliminations | ¥294m | −¥1.5bn |
| Total | ¥1.13T | ¥220.9bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.